- Home
- AMLX vs NNNN Comparison
AMLX vs NNNN Comparison
Compare AMLX & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMLX | NNNN |
|---|---|---|
| Founded | 2014 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2022 | 2025 |
Fundamental Metrics
Financial Performance| Metric | AMLX | NNNN |
|---|---|---|
| Price | $15.72 | $29.80 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $17.43 | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 35.5K |
| Earning Date | 03-03-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | N/A | ★ $6,920,153.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $513.58 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.60 | $5.18 |
| 52 Week High | $17.49 | $55.65 |
Technical Indicators
Market Signals| Indicator | AMLX | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 65.02 | 45.85 |
| Support Level | $12.08 | $28.61 |
| Resistance Level | $17.49 | $33.96 |
| Average True Range (ATR) | 1.01 | 4.30 |
| MACD | 0.50 | -0.80 |
| Stochastic Oscillator | 73.42 | 8.27 |
Price Performance
Historical ComparisonAbout AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.